RBC Capital Markets downgrades Abcam to 'sector perform'
20th Jun 2023 11:18
(Sharecast News) - RBC Capital Markets downgraded Abcam on Tuesday to 'sector perform' from 'outperform' and cut the price target to $22 from $23 as it recommended investors take profit on bid anticipation.
Read moreBroker tips: Ocado, Abcam
20th Jun 2023 08:22
(Sharecast News) - Online supermarket Ocado was under the cosh on Tuesday after JPMorgan Cazenove cut its price target on the shares to 400p from 450p and placed the stock on 'negative catalyst watch' into first-half results.
Read moreSunday newspaper round-up: Bank of England, Sturgeon, Melrose
11th Jun 2023 14:36
(Sharecast News) - Experts believe that the Bank of England will have to jack up its base rate from 4.5% at present to 5.5% by the end of 2023 in order to tame stubbornly high inflation. It was that prospect that had already resulted in lenders and building societies to raise the cost of fixed-rate mortgages or to pull deals altogether, as HSBC did during the preceding week. Higher rates also have implications for the cost of servicing the country's debts, in turn eliminating the Chancellor's already limited headroom to push through tax cuts before the elections. - The Financial Mail on Sunday
Read moreAbcam delisting from AIM going ahead this week
12th Dec 2022 09:14
(Sharecast News) - Life science research tool specialist Abcam updated the market on the cancellation of its shares on AIM on Monday, which it first announced on 17 October.
Read moreRBC Capital Markets lowers target price on Abcam
10th May 2022 10:13
(Sharecast News) - Analysts at RBC Capital Markets lowered their target price on protein research tools producer Abcam from 1,950.0p to 1,700.0p on Tuesday in order to better reflect share price movements at competitors.
Read moreBioVision acquisition helps lift Abcam in 2021
27th Jan 2022 16:04
(Sharecast News) - Life science supplier Abcam said in a trading update on Thursday that it expected total revenues of around £315m for 2021, representing growth of more than 22% at constant exchange rates, and 17% on a reported basis.
Read moreAbcam completes earnings-accretive BioVision acquisition
27th Oct 2021 08:48
(Sharecast News) - Science research tools company Abcam announced on Wednesday that it has completed its acquisition of BioVision from Boai NKY Medical Holdings, for total consideration of $340m.
Read moreAbcam to buy BioVision for $340m
2nd Aug 2021 09:48
(Sharecast News) - Abcam said on Monday that it has agreed to buy California-based BioVision for $340m.
Read moreAvacta signs global distribution deal with Abcam
6th Apr 2021 11:03
(Sharecast News) - Cancer therapies and diagnostics developer Avacta Group has entered into a global distribution agreement with Abcam, it announced on Tuesday, to sell its recently-developed SARS-CoV-2 research 'ELISA Affimer' reagents.
Read moreTuesday broker round-up
12th Jan 2021 13:14
(Sharecast News) - Clarkson: JP Morgan downgrades to neutral with a target price of 2,960p.
Read moreThursday broker round-up
17th Dec 2020 13:13
(Sharecast News) - Yellow Cake: Berenberg reiterates buy with a target price of 300p.
Read moreRBC downgrades Abcam, leaves price target unchanged
9th Nov 2020 11:46
(Sharecast News) - RBC Capital Markets has downgraded its rating on life sciences firm Abcam, sending the shares lower.
Read moreThursday broker round-up
22nd Oct 2020 13:59
(Sharecast News) - Abcam: Berenberg downgrades to hold with a target price of 1,180p.
Read moreBerenberg lowers rating on ABCAM to 'hold'
22nd Oct 2020 12:07
(Sharecast News) - Analysts at Berenberg lowered ABCAM to 'hold' from 'buy' on Thursday, highlighting what it called "the real Covid-19 impact".
Read moreTuesday broker round-up
22nd Sep 2020 13:28
(Sharecast News) - Imperial Brands: RBC Capital Markets upgrades to outperform with a target price of 1,900.0p.
Read more